Economic cost of age-related macular degeneration: A review of recent research

Drugs and Aging

Volumn 23, Issue 3, 2006, Pages 217-225

  Ke, Kathleen M ^a   Chakravarthy, Usha ^b   O'Neill, Ciaran ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; VITAMIN; ZINC;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPED COUNTRY; DRUG COST; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCIENTIFIC LITERATURE; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

AGED; AGING; BIOMEDICAL RESEARCH; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATABASES, BIBLIOGRAPHIC; HEALTH CARE COSTS; HEALTH PLANNING; HUMANS; MACULAR DEGENERATION; MODELS, ECONOMIC;

EID: 33645758289     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623030-00004     Document Type: Review

References (35)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844-52
2. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004; 44 (4): 17-39
3. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108: 697-704
4. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol 1996; 80 (1): 9-14
5. Hyman L. Epidemiology of AMD. In: Hampton GR, Nelson PT, editors. Age-related macular degeneration: principles and practice. New York: Raven, 1992: 1-35
6. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000; 342 (7): 483-92
7. Hart PM, Chakravarthy U, Stevenson MR, et al. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol 1999; 83 (10): 1115-20
8. Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psych 2002; 10 (3): 305-10
9. Age-Related Eye Disease Study (AREDS) Group. A randomised, placebo-controlled, clinical trial of high-dose supplementa tion with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: report number 8. Arch Ophthalmol 2001; 119: 1417-36
10. Falsini B, Piccardi M, Iarossi G, et al. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 2003; 110 (1): 51-60
11. Koh HH, Murray IJ, Nolan D, et al. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp Eye Res 2004; 79 (1): 21-7
12. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75 (4): 216-30
13. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
14. Øvretveit J. Evaluating health interventions. Maidenhead: Open University Press, 1998
15. Bonastre J, Le Pen C, Soubrane G, et al. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181-90
16. Garattini L, Castelnuovo E, Lanzetta P, et al. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments: a multicenter, prospective 1-year study. Eur J Health Econ 2004; 5 (1): 22-7
17. Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 2002; 3 (2): 94-102
18. Brown GC, Brown MM, Sharma S, et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000; 107: 1374-80
19. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001; 16 (4): 218-22
20. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age-related macular degeneration. Br J Ophthalmol 2004; 88 (8): 982-7
21. Hopley C, Salkeld G, Wang JJ, et al. Cost utility of screening and treatments for early age-related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88: 450-4
22. Husereau DR, Shukla V, Skidmore B, et al. Photodynamic therapy with verteporfin for the treatment of neovascular age-related macular degeneration: a clinical assessment. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2002; 31: 40
23. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003; 87 (10): 1201-4
24. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003; 7 (9): v-vi, 1-98
25. National Institute for Clinical Excellence. Final appraisal determination: photodynamic therapy for age-related macular degeneration [online]. Available from URL: http://www.nice.org.uk/page.aspx?.o = 32774 [Accessed 2005 Jan 28]
26. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108 (11): 2051-9
27. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004; 88 (9): 1107-12
28. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in Australia. Clin Exp Ophthalmol 2000; 28 (3): 140-2
29. O'Neill CE, Jamison J, McCulloch D, et al. Age-related macular degeneration: cost-of-illness issues. Drugs Aging 2001; 18 (4): 233-41
30. Hopley C, Carter R, Mitchell P. Measurement of the economic impact of visual impairment from age-related macular degeneration in Australia. Clin Experiment Ophthalmol 2003; 31 (6): 522-9
31. Curtis L, Netten A. Unit costs of health and social care 2004. Canterbury: Personal Social Services Research Unit, 2004
32. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108 (10): 1893-901
33. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999; 97: 473-511
34. Brown GC, Sharma S, Brown MM, et al. Utility values and age-related macular degeneration. Arch Ophthalmol 2000; 118 (1): 47-51
35. Williams R, Brody B, Thomas R, et al. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998; 116 (4): 514-21